(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 11 Aug 2017 The study is now recruiting subjects.
- 08 Aug 2017 Planned number of patients changed from 398 to 208.
- 08 Aug 2017 Planned End Date changed from 1 Dec 2015 to 1 Mar 2018.